Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Findings from University of Arkansas advance knowledge in cancer vaccines
April 30th, 2008
According to a study from the United States, "The safety and immunogenicity of the human papillomavirus type 16 (HPV16) or HPV18 (HPV16/18) E7 antigen-pulsed mature dendritic cell (DC) vaccination were evaluated for patients with stage 113 or IIA cervical cancer. Escalating doses of autologous DC (5, 10, and 15 X 106 cells for injection) were pulsed with recombinant HPV16/18 E7 antigens and keyhole limpet hemocyanin (KLH; an immunological tracer molecule) and delivered in five subcutaneous injections at 21-day intervals to 10 cervical cancer patients with no evidence of disease after they underwent radical surgery." "Safety, toxicity, delayed-type hypersensitivity (DTH)...
Source: Vaccine Weekly (2008-04-30)
|
